Prescription Drug News and Research

RSS

AARP opposes Idaho Health Freedom Act

In a move that could have dire effects on health care in Idaho, the Senate State Affairs Committee voted yesterday to bring the Idaho Health Care Freedom Act (House Bill 391) one step closer to becoming law

19 Feb 2010

Medicare coverage for prescription drugs: HHS to apply ARRA increased FMAP to clawback payments

HHS Secretary Kathleen Sebelius today announced $4.3 billion in financial relief to states by reducing the amount they will have to pay the federal government to offset the cost of Medicare coverage for prescription drugs for state residents eligible for both Medicare and Medicaid.

19 Feb 2010

Report examines how medical technology changes state of health care

Federal researchers Wednesday released a report that examines how medical technology is changing the state of health care.

19 Feb 2010

FDA accepts filing of Jazz Pharmaceuticals' NDA for sodium oxybate

Jazz Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted for filing the New Drug Application (NDA) for JZP-6 (sodium oxybate) for the treatment of fibromyalgia.

19 Feb 2010

WellCare Health Plans reports net income of $39.9M for 2009

WellCare Health Plans, Inc. today reported results for the year and fourth quarter ended December 31, 2009. As determined under generally accepted accounting principles (“GAAP”), the Company reported net income of $39.9 million, or $0.95 per diluted share, for the year 2009, compared with a net loss of $36.8 million, or $0.89 per diluted share, for the year 2008.

18 Feb 2010

Patient-centered medical home concept to benefit pharmaceutical industry

HealthLeaders-InterStudy, a leading provider of managed care market intelligence, reports that the pharmaceutical industry stands to gain from the patient-centered medical home concept that continues to gain traction across the country. According to the recent New England Health Plan Analysis, medical home projects seek to maintain costs and improve health through better treatment compliance, including prescription drug regimens.

18 Feb 2010

Medication therapy management programs for Aetna Medicare members

Aetna today announced that members who enroll in its 2010 Medicare plans will have access to enhanced services called medication therapy management (MTM) aimed at helping them safely and effectively take medications prescribed by their physician. MTM, which will be delivered by Mirixa Corporation, brings together pharmacists, patients, physicians and other health care professionals to help patients with their medications.

18 Feb 2010

Walgreen acquires Duane Reade for total enterprise value of $1.075 billion

Walgreen Co. and New York-based drugstore chain Duane Reade Holdings, Inc. today announced a definitive agreement under which Walgreens will acquire Duane Reade from affiliates of Oak Hill Capital Partners in a cash transaction for a total enterprise value of $1.075 billion, which includes the assumption of debt.

17 Feb 2010

Nebraska laws to protect patients and healthcare providers against unfair prescription insurance practices

Dozens of patients and state and national advocacy and healthcare groups, including Nebraska Medical Association and Nebraska Nurses Association, today urged passage of two precedent-setting consumer protection healthcare bills during a hearing at the Nebraska State Capitol. These laws would be the first in the nation to protect patients and healthcare providers against unfair prescription insurance practices.

17 Feb 2010

Covidien's Exalgo NDA: FDA sets new PDUFA action date

Covidien today announced that the U.S. Food and Drug Administration has set a new action date of March 1, 2010, under the Prescription Drug User Fee Act (PDUFA) for the review of the New Drug Application (NDA) for Exalgo™ (hydromorphone HCl) Extended-Release Tablets, (CII).

17 Feb 2010

AZ&Me Prescription Savings programs help 13% more patients in 2009

AstraZeneca announced today that it provided $769.6 million in savings to 507,475 patients in the United States last year through its AZ&Me™ Prescription Savings programs.

17 Feb 2010

Study shows value-based plans can improve adherence for diabetes medicines

A study by CVS Caremark (NYSE: CVS), published this week in the American Journal of Pharmacy Benefits, finds that insurance benefit designs that reduce the cost of medications for plan participants result in patients being more likely to start and stay on their medication therapy.

17 Feb 2010

FDA extends CombinatoRx' Exalgo tablets NDA PDUFA review date

CombinatoRx, Incorporated today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for review of the Exalgo™ (hydromorphone HCl) extended-release tablets New Drug Application (NDA) from Monday, February 22, 2010 to Monday, March 1, 2010 due to federal government closings.

16 Feb 2010

Meda publishes 2009 year-end report

“The Meda Group expects to achieve sales of about SEK 13,000 million and an EBITDA of about SEK 4,200 million for full-year 2009.”

16 Feb 2010

Case study demonstrates positive impact of diabetes management program

A case study published in the current issue of the American Journal of Health-System Pharmacists, demonstrates the positive impact of a diabetes management program designed to educate and motivate members to engage in their health care. The program was implemented by CVS Caremark and Polk County, Florida, a self-insured government employer client.

16 Feb 2010

Today's OpEds: Republicans and Medicare, small business health costs and changes to FEHBP

Republican leaders are now saying they will not participate in the meeting unless the president takes his health reform plan off the table to start over. I understand their concerns with a variety of issues in the current bills, but where you start is not nearly as important as where you finish. After all, fees continue to skyrocket and millions remain uninsured, costing our country in many ways. ... There is no time like the present for Washington to show America that it is interested in governing, not just in campaigning. The cameras will be rolling, and we will be watching (Christine Todd Whitman, 2/12).

14 Feb 2010

Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease

Shire plc, the global specialty biopharmaceutical company, today presented positive results from its first Phase III study (TKT 032) evaluating safety and efficacy of velaglucerase alfa, its investigational enzyme replacement therapy for the treatment of Type 1 Gaucher disease. The data were presented in an oral presentation at the Lysosomal Disease Network (LDN) World Symposium in Miami, Florida.

12 Feb 2010

HealthSpring enters into $350M senior secured credit facility

HealthSpring, Inc. today announced that it has entered into a new $350 million senior secured credit facility. The new agreement consists of $175 million in five-year term loans and a four-year, $175 million revolving credit facility, $25 million of which was drawn at closing. Outstanding loans under the new credit facility bear interest at a spread over a base rate or LIBOR (initially 325 basis points), depending on the Company’s total leverage ratio.

12 Feb 2010

'CARES by GSK' introduces oncology co-pay assistance program

GlaxoSmithKline today announced the launch of CARES by GSK, a comprehensive program that provides a single point of contact to GSK services and programs designed to improve access to GSK oncology and specialty medications. In addition to the comprehensive offerings that include specialty reimbursement services and free medicine, CARES by GSK now offers its first oncology co-pay assistance program to further help eligible patients with limited insurance coverage to have better access to GSK oral oncology and specialty medicines.

11 Feb 2010